Loncar China BioPharma ETF Stock Price, News & Analysis

Loncar China BioPharma ETF (Symbol: CHNA) was an Exchange Traded Fund (ETF) focused on the biotechnology sector within China. It aimed to provide investors with targeted exposure to Chinese pharmaceutical and biotech companies that are contributing significantly to the global healthcare industry.

As of October 20, 2023, the CHNA ETF has been successfully reorganized into the Range Cancer Therapeutics ETF (CNCR). This reorganization was completed by Exchange Traded Concepts, LLC. Upon the Nasdaq Stock Market opening on October 23, 2023, shareholders of CHNA began holding shares of CNCR, with the net asset value (NAV) of these new shares equating to the NAV of their previous CHNA shares.

The reorganization was a taxable event, and shareholders may recognize a gain or loss for federal income tax purposes. Detailed information regarding this process was provided in the Information Statement/Prospectus filed with the SEC. Post-reorganization, CNCR issued approximately 380,835.056 new shares, resulting in total assets of approximately $11,536,010 and a NAV per share of $9.77.

The Loncar China BioPharma ETF, during its operation, was designed to track the performance of a specific index that included key players in China's biopharmaceutical landscape. Investors interested in the sector can continue to access similar opportunities through the CNCR ETF, which now encompasses these holdings.

For up-to-date information and details on the new CNCR ETF, investors are advised to visit the official website at https://www.rangecncr.com/ or contact 1-800-617-0004.

Disclaimer: Investing in ETFs involves risks, including the potential loss of principal. ETFs trade like stocks, and their market prices may vary from their NAV. Investors should carefully consider the investment objectives, risks, charges, and expenses of the Fund before investing, as detailed in the prospectus.